SS-31
Elamipretide — Mitochondria-Targeting Peptide
SS-31 (Elamipretide) is a mitochondria-targeting tetrapeptide that accumulates in the inner mitochondrial membrane and stabilizes cardiolipin — a phospholipid essential for electron transport chain function. Its ability to directly access and protect mitochondria distinguishes it from most longevity compounds that act upstream.
At a Glance
The inner mitochondrial membrane is the site of ATP synthesis and is also highly vulnerable to oxidative damage. SS-31's affinity for cardiolipin concentrates it precisely where mitochondrial dysfunction originates — making it a targeted tool rather than a general antioxidant.
Cardiolipin stabilization has downstream effects throughout the electron transport chain: improved Complex I, II, and IV activity; reduced reactive oxygen species production; and maintained mitochondrial membrane potential. These effects have been studied in cardiac, renal, and skeletal muscle tissue.
Phase 2 clinical trials in primary mitochondrial myopathy and heart failure with preserved ejection fraction (HFpEF) have provided human evidence for its cardiac protective properties.
Cardiolipin Stabilization
Concentrates in the inner mitochondrial membrane and stabilizes cardiolipin — a phospholipid essential for organizing the electron transport chain supercomplexes.
ETC Function Restoration
Improves electron transport chain complex activity (I, II, IV), restoring ATP production efficiency in dysfunctional mitochondria.
ROS Reduction
Reduces reactive oxygen species production at the mitochondrial source rather than scavenging them downstream — a more fundamental intervention than conventional antioxidants.
Cardioprotection
Studied in cardiac ischemia-reperfusion models, heart failure models, and Phase 2 HFpEF trials for direct mitochondrial cardiac protection.
- Cardiac ischemia-reperfusion injury — one of the most studied applications in preclinical literature
- Heart failure with preserved ejection fraction (HFpEF) — Phase 2 trials underway
- Primary mitochondrial myopathy — clinical trials for genetic mitochondrial diseases
- Renal ischemia and acute kidney injury models
- Skeletal muscle aging and sarcopenia — mitochondrial contribution to muscle loss
- Neurodegenerative disease models — mitochondrial dysfunction in Parkinson's, Alzheimer's
- Age-related mitochondrial decline — energy production restoration in aging tissue
SS-31's unique ability to directly access the inner mitochondrial membrane — a compartment most drugs and peptides cannot reach — makes it a high-value research tool in mitochondrial biology.
| Aspect | SS-31 | NAD+ | MOTS-c |
|---|---|---|---|
| Target | Inner mitochondrial membrane | NAD+/sirtuin pathway | Mitochondrial DNA-encoded |
| Primary Action | Cardiolipin stabilization, ETC | Sirtuin activation, ATP | AMPK activation, metabolism |
| Administration | SC or IV injection | IV, SC, or oral precursors | SC injection |
| Clinical Data | Phase 2 (cardiac, myopathy) | Multiple Phase 1/2 | Early clinical |
| Best Research Use | Mitochondrial dysfunction, cardiac | Longevity, metabolism | Metabolic, longevity |
Direct mitochondrial access — accumulates at the inner membrane where dysfunction originates
Phase 2 clinical data — human evidence in cardiac and myopathy populations
Mechanistically precise — cardiolipin stabilization is a specific and well-characterized target
Parenteral administration required — no oral bioavailability; SC or IV only
This overview is strictly educational and based on publicly available scientific literature as of 2026. It does not constitute medical advice. All Helixera Labs products are for laboratory research use only. Not for human or veterinary use. · Helixera Labs LLC © 2026